Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0032463 (polycythemia vera)
 3,374 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Possibilities and limits of radiotherapy are described in a survey in the following diseases: Undifferentiated cell leucoses: The radiotherapy of the central nervous system brings an increase of the 5-year survival rates, since the localisations in this region existing in 45-70% are only insufficiently reached by the cytostatic substances because of the defective blood-liquor passage. On the other hand, other indications to radiotherapy recede into the background. Chronic leucoses: In the foreground of the application is the ray-therapy of the spleen, of which, apart from the local effect on the splenic tumour, also an improvement of the remission rates is expected. At adequate indication also the ray-therapy of infiltrates in the lymph nodes and other localisations achieves good palliative results. The extra-corporeal irradiation of blood is a method, the usability of which must still be proved. With the introduction of the modern cytostatic drugs the exposure of the whole body has lost significance. Lymphogranulomatosis: In this disease the radiotherapy has caused a decisive change: In these cases the recognition of the local development of the disease and its continuous spreading was decisive, and issuing from this also the simultaneous irradiation of the defluxion areas and the application of an oncolytic dose. According to the stage with or without combination of cytostatic drugs an exact plan of therapy is made. Here healing rates of 70-80% in stage I are to be expected. Myeloma: Here the radiotherpy has palliative tasks, with correct indication good effects are to be expected. Polycythaemia vera: In this disease radiotherapy in form of incorporation of radioactive phosphorus is the remedy of choice.
 ...
PMID:[Radiotherapy of hematologic diseases]. 6 Aug 34

The authors report the clinical and hematological course of 20 patients with polycythemia vera complicated by acute leukemia. This was responsible for 35,8% of the 53 deaths in the series of 103 patients treated with radioactive phosphorus. It occurred on average 12 years after the first treatment. The data in these cases are compared with those in the literature. The role of ionising radiation and/or the myelo-proliferative syndrome itself in the onset of acute leukemia is discussed.
 ...
PMID:[Acute leukemia and primary Vaquez' polycythemia. 20 cases]. 21 57

A patient with polycythemia vera (PV) received successive treatment by phlebotomies, radioactive phosphorus, myleran and cyclophosphamide. Sixteen years after the diagnosis, he developed acute myeloblastic leukemia. A complete remission was achieved following two courses of COAP (cyclophosphamide, vincristine, Cytosine Arabinoside, and prednisone) therapy. Four months later, while still in leukemic remission, he became mildly polycythemic again and the treatment with phlebotomies and cyclophosphamide was resume. The patient has subsequently been in complete remission of leukemia for over three years and his polycythemia is controlled by small doses of cyclophosphamide. This appears to be a unique case of such a prolonged remission of leukemia in the course of PV, with a return to a mild polycythemia state.
 ...
PMID:Prolonged remission of leukemia associated with polycythemia vera. 26 98

Systemic mastocytosis occurred as a fatal event in a patient with long-standing polycythemia vera. The patient had been treated over the course of 21 yr with radioactive phosphorus. Possible relationships between mastocytosis and polycythemia vera, and also between mastocytosis and treatment with ionizing radiation, are discussed. Histopathologic and electron microscopic findings are illustrated. Difficulties in establishing the diagnosis of mast cell disease in this setting are also described.
 ...
PMID:Systemic mastocytosis in a patient with polycythemia vera treated with radioactive phosphorus. 30 Feb 55

32P is effective therapy for polycythemia and primary thrombocytosis. The Polycythemia Vera Study Group is comparing radioactive phosphorus with alkylating agents to determine relative efficacy. Less well investigated is the effectiveness of 32P vs. busulfan in chronic granulocytic leukemia. Endolymphatic administration of radiopharmaceuticals may play a role in the therapy of infradiaphragmatic lymphoma. Among the radionuclides that have at times been used in hematology are 32P, 198Au 24Na, 76As, 89Sr, 52Mb, 54Mn, 91Y, 95Zr, 95Cb, 111Ag, 109Pd, 131I, 185W, and 192Ir. As stated, 32P has proven single most efficacious agent. The hematologic diseases that have been treated include both malignant and benign conditions. Among the malignant conditions are polycythemia vera, agnogenic myeloid metaplasia, thrombocythemia, leukemia, Hodgkin's disease, and multiple myeloma. Hemophilia, and Osler--Weber--Rendu disease are among the benign entities in which the agents have been tried. Polycythemia and thrombocythemia remain those in which the greatest success has been achieved.
 ...
PMID:Radionuclide therapy of hematologic disorders. 48 47

A group of 52 consecutive patients with polycythemia vera was submitted to long-term therapy with radioactive phosphorus (32P). Initial phase of therapy induced complete remissions (normalization of hematogram; spleen not palpable) in 45% of the patients, and partial remissions in the remaining 55%. During maintenance therapy of the complete remission group, mean remission time was about 3.5 years. Individual remission times ranged between 1 and 6 years. In the group of patients with incomplete remission, mean remission time increased with the progression of the disease due to gradual development of "spent" -polycythemia. In patients with splenomegaly, remission time was negatively correlated to spleen size. In both groups the increment of annual accumulated dose averaged 2.4 mCi 32P. When considering polycythemia related causes of death only, mean survival time attained 12 years after initial treatment with 32P. Acute leukemia occurred in 2 patients (4%).
 ...
PMID:32P-therapy in polycythemia vera. 80 69

A 74-year-old white man with established polycythemia vera was treated with radioactive phosphorus after phlebotomies alone failed to control his disease. About 2 3/4 years later he died of multiple myeloma. The mutagenic effect of radioactive phosphorus may have caused or possibly accelerated preexisting myeloma. Basic nonmalignant disease deserves careful consideration before radiation or radiomimetic agents are used. One might consider a probably less mutagenic drug such as hydroxyurea in patients with polycythemia vera when phlebotomy alone does not give good control of red cell mass and thrombocytosis.
 ...
PMID:Multiple myeloma on polycythemia vera following radioactive phosphorus therapy. 101 58

In a group of 172 cases of polycythemia vera treated with radioactive phosphorus acute granulocytic leukemia developed in 3 and chronic granulocytic leukemia in 6 cases. The author believes that development of acute granulocytic leukemia during this treatment may be considered with some probability as a result of the leukemia-inducing action of ionizing radiation. Transition of polycythemia vera into chronic granulocytic leukemia seems to be a natural outcome of this complex myeloproliferative syndrome in patients with survival prolonged by treatment with 32P.
 ...
PMID:Observations on polycythemia vera turning into acute or chronic granulocytic leukemia during treatment with radioactive phosphorus 32P. 106 85

Retrospective studies were carried out in 52 patients with polycythemia vera who were treated with radioactive phosphorus (32-P) over periods ranging between 4 and 24 years. Control of hematopoiesis was achieved in all patients. Duration of the remission induced differed considerably in the individual patients. Mean remission lasted 3-4 years. After 13 years of 32-P treatment, the mean duration of remission lengthened due to gradual transition of some cases into "spent" polycythemia. The mean annual dose of 32-P was about 2.4 mCi. In patients with long-term remissions, the dose accumulated per year was markedly less. These patients probably represent optimal preconditions for 32-P therapy. Mean survival was 12.5 years. The majority of the patients died from thorombo-embolie events or hemorrhage; incidence of acute leukemia was about 4%.
 ...
PMID:[Experiences with radioactive phosphorus therapy in cases of polycythemia vera (author's transl)]. 112 54

Incorporation of [32P]-orthophosphate into plasma phospholipids was investigated in 11 patients with polycythemia vera. The specific activity of phospholipid radioactive precursors (TCA-extract) was maximal 1 hour after the delivery of radioactive phosphorus and dropped to less than 20 per cent of maximal value after 24 hours. The peak of total phospholipid specific activity was observed 48 hours after the administration of [32P]-orthophosphate in 10 patients, and after 24 hours in one, and decreases regularly afterward. The half-life of the lipid-bound phosphorus in the plasma of investigated patients, determined during the decrease of their specific activity was 252+/-60 hours. Concentration of total plasma phospholipids and the pattern of individual phospholipid found in patients with polycythemia vera were similar to those reported for normal individuals. The rate of incorporation of the labeled phosphorus into phosphatidylethanolamine and phosphatidic acid was much more rapid than into lysophosphatidylcholine, sphingomyelin, or phosphatidylcholine.
 ...
PMID:Incorporation of [32P]-orthophosphate into total and individual plasma phospholipids in patients with polycythemia vera. 115 Nov 51


1 2 3 4 Next >>